Zynerba Pharmaceuticals (ZYNE) Earning Somewhat Positive Media Coverage, Study Shows
News articles about Zynerba Pharmaceuticals (NASDAQ:ZYNE) have trended somewhat positive on Monday, according to Accern. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zynerba Pharmaceuticals earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.7001531442065 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) – Eye-Catching Shares – Nasdaq Journal (press release) (nasdaqjournal.com)
- BRIEF-Zynerba Pharmaceuticals Inc Plans To Initiate Phase 2 Development Of ZYN001 In Tourette Syndrome By Year End (reuters.com)
- Zynerba Pharmaceuticals, Inc. (ZYNE) Stock Technical Analysis – Wall Street Morning (wallstreetmorning.com)
- Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update – GlobeNewswire (press release) (globenewswire.com)
Several equities research analysts recently weighed in on ZYNE shares. Oppenheimer reissued a “hold” rating on shares of Zynerba Pharmaceuticals in a research report on Friday, September 29th. Zacks Investment Research raised shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, December 8th. Piper Jaffray Companies raised shares of Zynerba Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the company from $7.00 to $16.00 in a research report on Thursday, September 28th. Cantor Fitzgerald set a $17.00 price target on shares of Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, November 20th. Finally, Canaccord Genuity raised their price target on shares of Zynerba Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, September 29th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $15.00.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) traded down $0.20 during trading hours on Monday, reaching $12.49. 339,900 shares of the company’s stock were exchanged, compared to its average volume of 494,000. Zynerba Pharmaceuticals has a fifty-two week low of $5.42 and a fifty-two week high of $25.95. The company has a market cap of $171.17 and a P/E ratio of -4.82.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its earnings results on Tuesday, November 14th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.05). During the same period last year, the company earned ($0.67) EPS. equities research analysts expect that Zynerba Pharmaceuticals will post -2.49 EPS for the current year.
In related news, major shareholder Michael Rapp bought 15,000 shares of the business’s stock in a transaction on Tuesday, January 2nd. The stock was acquired at an average price of $12.99 per share, with a total value of $194,850.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last ninety days, insiders acquired 85,000 shares of company stock valued at $875,161. 9.91% of the stock is currently owned by insiders.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.